Leap Therapeutics (NASDAQ:LPTX) Cut to “Neutral” at Robert W. Baird

Leap Therapeutics (NASDAQ:LPTX) was downgraded by stock analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a report released on Wednesday,Briefing.com Automated Import reports. They presently have a $1.25 target price on the stock, down from their prior target price of $9.00. Robert W. Baird’s price target indicates a potential upside of 92.31% from the stock’s current price.

Separately, HC Wainwright reiterated a “buy” rating and issued a $5.50 price target on shares of Leap Therapeutics in a report on Thursday, January 16th.

Leap Therapeutics Trading Down 71.1 %

LPTX opened at $0.65 on Wednesday. The company has a market cap of $24.91 million, a P/E ratio of -0.34 and a beta of 0.17. The company has a fifty day moving average price of $2.86 and a two-hundred day moving average price of $2.77. Leap Therapeutics has a 1-year low of $0.62 and a 1-year high of $4.79.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Simplify Asset Management Inc. lifted its position in Leap Therapeutics by 67.4% in the 3rd quarter. Simplify Asset Management Inc. now owns 1,056,895 shares of the company’s stock valued at $2,716,000 after acquiring an additional 425,626 shares in the last quarter. Key Client Fiduciary Advisors LLC lifted its holdings in shares of Leap Therapeutics by 12.2% in the fourth quarter. Key Client Fiduciary Advisors LLC now owns 361,253 shares of the company’s stock valued at $1,039,000 after purchasing an additional 39,330 shares in the last quarter. Geode Capital Management LLC grew its holdings in Leap Therapeutics by 18.0% during the third quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock worth $847,000 after buying an additional 50,194 shares in the last quarter. Exome Asset Management LLC purchased a new stake in Leap Therapeutics in the 3rd quarter valued at $264,000. Finally, Marshall Wace LLP lifted its stake in Leap Therapeutics by 268.2% during the 2nd quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock valued at $156,000 after acquiring an additional 58,094 shares in the last quarter. 30.46% of the stock is currently owned by institutional investors and hedge funds.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.